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Data from over 20 years ago demonstrated potential use for insulin-like growth factor (IGF)
signaling modulators, speciﬁcally with IGF-1R antagonists, in a variety of pediatric and
adolescent cancers, particularly in sarcomas. However, in spite of promising preclinical
data, IGF-1R inhibitors have not had the success as single agents that was originally hoped
for in clinical trials. Several potential mechanisms exist by which tumors are resistant to
IGF-1R inhibitors. Notably, these resistance mechanisms are currently best understood
in Ewing sarcoma and alveolar rhabdomyosarcoma. Various treatment schema have been
proposed as a potential way to overcome this resistance. The use of IGF-1R inhibitors,
mechanisms of resistance, and current ongoing clinical studies using IGF-1R inhibitors in
pediatric cancers are reviewed here.
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INTRODUCTION
The insulin-like growth factor (IGF) pathway regulates cellular
growth, proliferation, and survival, and is important in the devel-
opment of several cancers, including pediatric sarcomas, gliomas,
neuroblastoma, and medulloblastoma. There are three main lig-
ands that activate the IGF signaling cascade: IGF1, IGF2, and
insulin. These ligands are bound to one of six binding proteins
in circulation, IGFBP1–6. The IGF binding proteins, in particular
IGFBP3, are implicated in modulating interactions between lig-
and and receptor. Some have negative effects on receptor signaling
by competing for ligand. Others, notably IGFBP2 and IGFBP5,
amplify IGF signaling (reviewed in Grimberg and Cohen, 2000).
Higher levels of extracellular IGFBP3 are thought to decrease
signaling via IGF-1R even independent of ligand (Ricort and
Binoux, 2001). IGF binding proteins are also found intracellu-
larly. The IGF binding proteins have a wide range of functions
and have been implicated in signaling cascades other than IGF
signaling (reviewed in Grimberg and Cohen, 2000; Weroha and
Haluska, 2012). Further research is needed to elucidate their many
biological roles and their precise role in cancer development.
There are two IGF receptors, IGF-1R and IGF-2R, with IGF-
1R as the more important positive regulator of the IGF initiated
cascade as it is the only onewith an intracellular kinase domain (De
Meyts and Whittaker, 2002). In contrast to the activating effects of
IGF-1R signaling, IGF-2R is thought to be a negative regulator of
IGF signaling by binding extracellular IGF2 (Ghosh et al., 2003).
Unlike most other receptor tyrosine kinases, IGF-1R and insulin
receptors exist as dimers prior to ligand binding. These receptors
can act as either homodimers or a variety of heterodimers. Either
variation can take part in tumorigenesis.
Binding of ligand to IGF-1R leads to autophosphorylation
of the intracellular domain and recruitment of adapter
proteins, ultimately leading to activation of a signaling cascade
that can include modulation of PI-3-kinase/AKT/mTOR and
Ras/Raf/MAPK, leading to cell proliferation (reviewed in Pollack,
2008; Rikhof et al., 2009; Maki, 2010).
In spite of very encouraging preclinical results, initial clinical
studies of IGF-1R antagonists as a single agent have not demon-
strated the results that were initially anticipated in clinical trials.
Several potential mechanisms exist by which tumors are resis-
tant to IGF-1R inhibitors. Various treatment schema have been
proposed as a potential way to overcome this resistance. The
preclinical data in pediatric cancers, mechanisms of resistance,
and current ongoing clinical studies using IGF-1R inhibitors are
reviewed here.
ROLE OF IGF-1R IN PEDIATRIC CANCER
EWING SARCOMA
Ewing sarcoma is the second most common bone cancer in chil-
dren and adolescents. It can also occur in soft tissue. IGF-1R
signaling must be intact for Ewing sarcoma cell lines to prolif-
erate (Yee et al., 1990). Ewing sarcoma is characterized by IGF
pathway activating translocations of the EWSR1 gene. The most
common translocation, found in approximately 85% of Ewing
Sarcomas, is t(11;22) EWSR1-FLI1. The EWSR1-FLI1 gene prod-
uct directly inhibits the IGFBP-3 promoter (Prieur et al., 2004).
Since IGFBP-3 sequesters IGF-I from circulation (Lee and Rechler,
1996), the decreased levels of IGFBP-3 that result from the translo-
cation may increase the bioavailability of IGF-I, thus promoting
tumor growth (Kim et al., 2009). Initial preclinical testing showed
that murine monoclonal antibody alphaIR3, an IGF-1R antago-
nist, slows in vivo growth of Ewing sarcoma cells inmice (Scotlandi
et al., 1998). Testing by the Pediatric Preclinical Testing Program
further demonstrated that growth of some Ewing sarcoma cell
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lines is inhibited by IGF-1R inhibition (Kolb et al., 2008, 2011).
IGF-1R blockade can also be combined with other agents, specif-
ically vincristine, doxorubicin, or imatinib for synergy (Martins
et al., 2006).
ALVEOLAR RHABDOMYOSARCOMA
Rhabdomyosarcomas are divided into two histological subtypes:
embryonal, which represents about 70% of all rhabdomyosar-
coma, and alveolar, which represents about 30%; pleomorphic
rhabdomyosarcoma appears to be a genetically distinct sarcoma
that occurs principally in adults and not in children. Although
IGF activation has been implicated in driving the tumorigenicity
of both rhabdomyosarcoma types, the molecular characterization
of alveolar rhabdomyosarcoma (ARMS) is better understood and
is therefore the focus here.
Alveolar rhabdomyosarcoma is associated with a fusion pro-
tein resulting from translocations in the PAX3 or PAX7 genes
and FOXO1. The fusion protein activates the IGF-1R promoter,
resulting in increased receptor expression (Ayalon et al., 2001;
Xiao et al., 2002). AKT signaling secondary to up-regulation of
IGF-1R has also been implicated in having an inferior outcome
in ARMS patients with stage III disease, suggesting a way to risk
stratify patients (Petricoin et al., 2007). As in Ewing sarcoma, rhab-
domyosarcoma cell lines have demonstrated sensitivity to IGF-1R
inhibition (Kolb et al., 2008, 2011).
OSTEOSARCOMA
Osteosarcoma is the most common bone cancer in children
(Mirabello et al., 2009). Osteosarcoma cell lines are dependent
on IGF-1 via IGF-1R for in vitro growth (Kappel et al., 1994),
and IGF-1R expression has been associated with poor prognosis
(Wang et al., 2012). Nearly 20 years after that ﬁrst observation, a
mouse xenograft model using six different osteosarcoma cell lines
demonstrated objective responses to R1507, a monoclonal anti-
IGF1R antibody, in vivo. Two cell lines were resistant to R1507
(Kolb et al., 2008, 2010).
SYNOVIAL SARCOMA
Synovial sarcoma has a peak incidence around adolescence and
young adulthood (Spillane et al., 2000). It is characterized by
t(X;18) translocations which increase IGF pathway mediated sig-
naling (Sun et al., 2006). Higher IGF-1R expression has also been
associatedwithmore aggressive synovial sarcoma (Xie et al., 1999).
In preclinical studies, all of 15 synovial sarcomas tested showed sig-
niﬁcant IGF-II expression and 78% showed activated IGF-1R. The
IGF-1R inhibitor AEW541 had promising effects on proliferation.
It also impaired cell migration (Friedrichs et al., 2008).
WILMS TUMOR
The role of IGF-1R signaling in the pathogenesis of Wilms tumor
was proposed at least as early as 1989, when an anti-IGF-1R anti-
body slowed tumor growth in an in vivo model (Gansler et al.,
1989). Although Wilms tumor is generally responsive to current
treatment regimens, a relatively small proportion of patients will
develop recurrence (Kalapurakal et al., 2004). Increased gene copy
number of IGF-1R has been associated with recurrence, and in
general with worse outcomes in Wilms tumor (Natrajan et al.,
2006). In spite of this evidence, little progress has been made
studying the potential for IGF modulation in Wilms tumor. Initial
results using Wilms tumor cell lines were promising (Houghton
et al., 2010; Kolb et al., 2011), however technical difﬁculties grow-
ing and maintaining the cells in culture has hampered further
research. Most recently, a mouse xenograft model in which cells
from a Wilms tumor cell line were grown orthotopically within
mouse kidneywasused to show thatAEW541, an IGF-1R inhibitor,
reduced tumor growth (Bielen et al., 2012). It will be interesting
to see if this ﬁnding can be translated to additional Wilms tumor
cell lines, and in the clinic.
NEUROBLASTOMA
Neuroblastoma represents about 10% of pediatric malignancies
and is the most common cancer in the ﬁrst year of life. When
high risk or metastatic, survival rates are on the order of 40–50%
(Maris, 2010). Like several of the other tumor types discussed here,
IGF signalingwas implicated in the survival of neuroblastoma cells
decades ago (El-Badry et al., 1989). Neuroblastoma cell lines are
sensitive to the IGF-1R inhibitor BMS-536924 (Huang et al., 2009).
Additionally, IGF-1R is a major determinant of the metastatic
potential of neuroblastoma. Cell lines highly expressing IGF-1R
were much more likely to develop osteolytic lesions when injected
into mouse tibia compared to the same cells without IGF-1R.
This is thought to be secondary in part to IGF-1 chemoattraction
from bone stromal cells, allowing for a microenvironment that is
conducive to tumor growth (van Golen et al., 2006). More recent
laboratory studies showed that the addition of temozolomide to
anti-IGF-1R agents improved both in vitro and in vivo responses
compared to either agent alone. Interestingly, responsiveness to
anti-IGF-1R murine antibody EM164 was not related to IGF-1R
expression but was correlated with decreased AKT phosphoryla-
tion after treatment (Geoerger et al., 2010). Additional preclinical
studies showed both single agent anti-IGF-1R activity and addi-
tive effects when combined with more standard chemotherapies
in some neuroblastoma cell lines (Wojtalla et al., 2012).
GLIOBLASTOMA
Although usually seen in adults, glioblastoma does occur in
children. Genetically, pediatric gliomas are more commonly
associated with PDGFR-alpha aberrations compared to adult
gliomas, which are more commonly associated with aberrations
in EGFR signaling (Paugh et al., 2010). Gene ampliﬁcation of
IGF-1R has been shown in high grade pediatric gliomas (Bax
et al., 2010; Schiffman et al., 2010). Preclinical studies combining
IGF-1R inhibition with imatinib, which among other things
inhibits PDGFR, showed hints of activity that are encouraging
in this usually highly chemotherapy-resistant tumor type (Bielen
et al., 2011).
MEDULLOBLASTOMA
Medulloblastoma is the most common brain malignancy in chil-
dren, accounting for about 25% of all pediatric intracranial
cancers (Northcott et al., 2012). IGF-1R is highly expressed in
a majority of medulloblastoma, with one series reporting that
80% of medulloblastomas highly express IGF-1R (Del Valle et al.,
2002). There were hints of antiproliferative activity of R1507 in
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some medulloblastoma cell lines. Interestingly, response did not
seem to be correlated with level of IGF-1R expression (Wojtalla
et al., 2012).
GASTROINTESTINAL STROMAL TUMOR
Gastrointestinal stromal tumors (GIST) occur in both children
and adults. In adults, approximately 85% of GIST is at least par-
tially driven by mutations in KIT or PDGFRA, a ﬁnding that led to
the current imatinib- and sunitinib-based regimens used to treat
most adult GIST (Demetri et al., 2002, 2006). On the other hand,
pediatric GIST usually does not have the KIT and PDGFRA muta-
tions that normally characterize adult GIST (Prakash et al., 2005;
Janeway et al., 2007). This so-called wild type GIST is less respon-
sive to imatinib and sunitinib (Janeway et al., 2009; Janeway and
Pappo, 2012).
Insulin-like growth factor signaling dysregulation is also
present in GIST from both age groups. Adult GIST is more com-
monly characterized by overexpression of IGF2. Pediatric GIST
is more commonly associated with higher expression of IGF-1R
(Agaram et al., 2008; Janeway et al., 2010; Italiano et al., 2012). The
mechanism by which IGF-1R is overexpressed in these patients,
and its clinical signiﬁcance, remains unclear.
MECHANISMS OF RESISTANCE
RESISTANCE MECHANISMS AND PRECLINICAL DRUG COMBINATION
STUDIES IN EWING SARCOMA
Several different resistance mechanisms have been demonstrated
in Ewing sarcoma. Garofalo et al. (2012) described common path-
ways through which Ewing sarcoma cell lines are resistant to
multiple classes of IGF-1R antagonists. In all resistant lines tested,
IGF-1R was down-regulated in spite of maintenance of the ability
of treatment to lead to internalization and degradation of IGF-1R
after exposure to the drug, suggesting that alternative signaling
cascades independent of IGF-1R drive resistance. Up-regulation
of insulin receptor (IR)-A and IGF-II was seen in multiple cell
lines and seems to be one alternative signaling pathway allowing
for resistance (Garofalo et al., 2012). Similarly, resistant cell lines
also up-regulate the MAPK/ERK pathway. MAPK signaling was
recently demonstrated to be a compensatory mechanism in Ewing
sarcoma cell lines after exposure to an IGF-1R speciﬁc agent, par-
ticularly through phosphorylation of AKT (Huang et al., 2011).
Finally, Potratz et al. (2010) showed that BMS-536924 resistant
Ewing sarcoma cells up-regulated the activity of distal IGF-1R
signaling components such as mTOR and ribosomal protein S6
(RPS6). Cells that did not up-regulate these distal proteins were
sensitive to the IGF1R inhibitor. siRNA knockdown of RON
(MST1R, macrophage stimulating 1 receptor tyrosine kinase),
restored sensitivity in BMS-536294-resistant Ewing sarcoma cell
lines by decreasing RPS6 activation. In preclinical studies, at least
one Ewing sarcoma cell line demonstrated enhanced responsewith
IMC-A12 combined with rapamycin (Kolb et al., 2012).
RESISTANCE MECHANISMS AND PRECLINICAL DRUG COMBINATION
STUDIES IN ARMS
The observation of paradoxical activation of AKT with mTOR
inhibitors led to the development of combination treatment
using pretreatment with IGF-1R inhibitors in addition to mTOR
inhibitors (Wan et al., 2007). In vivo studies combining IGF-1R
inhibitors with rapamycin resulted in more sustained antitu-
mor effect compared to either agent alone in a mouse xenograft
model (Cao et al., 2008). In resistant ARMS cell lines, Huang et al.
(2010) demonstrated different resistant mechanisms for differ-
ent cell lines. In Rh41-807R cells, which are resistant to a small
molecule dual-kinase inhibitor blocking both IGF-1R and IR,
PDGFRAup-regulation proved to be the underlying cause of resis-
tance. In Rh41-MAB391R cells, resistant to MAB391, an IGF-1R
blocking antibody, AXL overexpression seems to be the culprit
leading to resistance, although this cause and effect relationship is
less clear.
IGF-1R-Her2 heterodimerization is another mechanism by
which RMS cells develop resistance to IGF modulating agents.
In vitro studies with ARMS cells demonstrated that co-treatment
with NVP-AEW541, an IGF1R inhibitor, combined with lapatinib,
a HER2 antagonist, reduced the phosphorylation of IGF-1R and
consequently decreased IGF mediated signaling in cells resistant
to IGF-1R modulators alone (Abraham et al., 2011).
RESISTANCE MECHANISMS AND PRECLINICAL DRUG COMBINATION
STUDIES IN OSTEOSARCOMA
The two cell lines that were resistant to R1507 in vivo, men-
tioned previously, both had evidence of MAPK phosphorylation
through mTOR signaling, representing a possible escape mecha-
nism in these lines after exposure to IGF-1R inhibition (Kolb et al.,
2010). More recently, two osteosarcoma cell lines were among
the lineages that showed enhanced activity when exposed to both
IGF-1R antibody with rapamycin (Kolb et al., 2012). Ultimately,
further studies are needed to assess the role of IGF modulation as
a potential treatment modality for osteosarcoma.
CLINICAL TRIALS
In clinical studies with IGF-1R antagonists alone, responses in
patients were seen in some Ewing sarcoma patients (Table 1) and
in isolated cases in patients with other cancers. Although some of
these responses were quite dramatic, as a whole these results and
the relatively small overall response rates are disappointing con-
sidering the plethora of promising preclinical data that preceded
the early clinical trials.
As a result of our relatively new understanding of the
role of alternative signaling pathways providing an avenue for
Table 1 | IGF-1R inhibitors in Ewing sarcoma (adapted from
Maki, 2012).
Reference Drug Phase Response (%)
Pappo et al. (2011) R1507 II 11/115 (9.6)
Juergens et al. (2011) Figitumumab I–II 15/106 (14)
Malempati et al. (2012) Cixutumumab I–II 1/35 (2.9)
Tap et al. (2012) Ganitumab II 1/18 (5.6)
Tolcher et al. (2009) Ganitumab I+tail 2/12 (16)
Olmos et al. (2010) Figitumumab I-II 2/16 (12)
TOTAL 41/312 (13)
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Table 2 | Clinical trials with IGF-1R antagonists including pediatric patients.
Trial # Drug Phase Sponsor/PI Status Publication
NCT00560144 R1507 I Hoffmann-La Roche Completed
NCT00609141 Cixutumumab I Suman Malempati, M.D. Completed Malempati et al. (2012)
NCT00976508 Figitumumab + Pegvisomant I Pﬁzer Terminated
NCT01182883 Cixutumumab +Temsirolimus I Dennis D Hickstein, M.D. Withdrawn prior to enrollment
NCT00617890 SCH 717454 II Merck Active, not recruiting
NCT00642941 R1507 II Hoffmann-La Roche Active, not recruiting Pappo et al. (2011)
NCT0161479 Cixutumumab+Temsirolimus II Lars M.Wagner, M. D. recruiting
IGF-1R antagonist resistance, canonical AKT activation has been
emphasized as a possible target for clinical development of
combination regimens. Clinical studies are currently underway
combining IGF-1R inhibitory agents withmTOR inhibitors. Some
encouraging responses were seen in these preliminary studies. In a
phase I dose-expansion trial combining the IGF-1R inhibitor cixu-
tumumab and mTOR inhibitor temsirolimus, 7 of 20 patients had
either stable disease or responses by RECIST criteria (35%), and
29% had tumor regression. Interestingly, one of the six patients
who had previously developed resistance to a different single agent
IGF1R inhibitor had a complete response (CR) in this study
(Naing et al., 2012). A second phase I study combining an IGF-
1R inhibitor and mTOR inhibitor, ﬁgitumumab and everolimus,
also saw cases of promising responses. This time, the most pro-
nounced response was in a patient with solitary ﬁbrous tumor
(Quek et al., 2011).
At least one phase II study is seeking to expand on the ﬁnd-
ings of the phase I studies combining IGF-1R and mTOR targeted
agents. Here, cixutumumab and temsorilimus had PFS rates of
32–42% after 12 weeks. Patients with Ewing sarcoma in the study
had a response rate of 20%, with responses seen also in osteosar-
coma, chondrosarcoma, and solitary ﬁbrous tumor patients.
Interestingly, in this study there was no clear correlation between
biochemical markers of IGF-1R or mTOR pathway inhibition and
clinical response (Schwartz et al., 2012).
Most of the studies discussed above were not targeted to
the pediatric population even though in many cases adoles-
cents and young adults were included. Seven clinical trials were
identiﬁed in the clinical trials database that were designed specif-
ically to assess pediatric cancer, including patients less than
16 years old. Of those studies identiﬁed, three are ongoing
and only one is actively recruiting patients as of early 2013
(Table 2).
FUTURE DIRECTIONS
In spite of the low response rates in most trials of IGF-1R
inhibitors, the dramatic images seen in the patients who did
respond encourage further research in this important signaling
pathway. We are only beginning to understand the mechanisms
by which cancers are resistant to IGF-1R targeted agents. Clinical
trials aimed at overcoming this resistance are now underway, and
more will surely aid in revealing which patients may best respond
to IGF-1R therapies, which may require a combination regimen,
and which may not respond at all. To date, very little is known
in terms of predicting who may respond. Our understanding of
the potential use of IGF-1R targeted agents is less well understood
in children compared to adults. Although there is a plethora of
basic science data both published and forthcoming, clinical data
are still lacking. IGF-1R inhibitors remain a promising focus of
investigation for pediatric cancer.
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